A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...

Merck & Co. announced Thursday it has agreed to buy Acceleron Pharma for $11.5 billion. If completed, the deal would be the largest biopharma acquisition this year, and a sign that Merck is willing to ...

Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted ...

The ruling maintains access to the drug while litigation continues. Mifepristone can still be prescribed at pharmacies or by ...

A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way ...

Three months ago, Vertex Pharmaceuticals shared news that investors were eagerly expecting. A drug the company developed for a rare genetic disease appeared to work as intended, executives said, ...

Aardvark shares fell as much as 36% in morning trading and, at just over $5 apiece, were worth less than half of their trading price before ARD-101’s troubles began. The situation has put the company ...